Cardinal Health, Inc. (CAH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Cardinal Health introduced fiscal 2027 EPS guidance in August calling for 13% to 15% growth, exceeding its long-term EPS growth target of 12% to 14%. At Morgan Stanley's Global Healthcare Conference, management was asked to detail the relative contribution from operating performance versus below-the-line factors including lower interest expense and tax-rate effects. The above-target earnings outlook is modestly positive for the company, though the excerpt provides no additional operating or financial-detail disclosures.

Analysis

The investable issue is not the headline EPS range but its composition. If the upside is primarily interest expense and tax normalization, CAH's earnings quality and terminal multiple should not re-rate materially; if it reflects Medical segment margin recovery, specialty-pharma mix, or sustainable operating leverage, consensus estimates for FY28 likely remain too low. Management needs to quantify the operating-profit contribution, working-capital assumptions, and whether any improvement is contract-specific versus repeatable across the customer base.

CAH's scale economics make incremental margin gains disproportionately valuable, but this is also a business where customer contract renewals can transfer most of those gains back to purchasers. Cencora (COR) and McKesson (MCK) are the relevant read-throughs: evidence of broad distributor pricing discipline would support the group, while CAH-specific improvement driven by a lagging Medical recovery would favor CAH on a relative basis. HCSG has no clear economic linkage to this development and should not be treated as a healthcare-services sympathy beneficiary.

Near term, a conference appearance without new KPIs is unlikely to be a durable catalyst. The 1-3 month catalyst is sell-side model revisions following management's reconciliation of operating versus below-the-line growth; the 6-18 month question is whether free-cash-flow conversion keeps pace with EPS, since inventory and receivables can obscure the quality of distributor earnings. A weaker-than-expected Medical profit trajectory, adverse customer pricing at renewal, or EPS growth materially reliant on tax/interest benefits would falsify the constructive relative thesis.

Key Decisions for Investors

• Maintain a watch, not a new outright CAH position, until management discloses the operating-income share of FY27 EPS growth and cash-flow conversion assumptions. Upgrade to long only if the majority of incremental EPS is operating-driven and FY28 consensus estimates begin rising; otherwise treat the guide as low-quality support rather than a re-rating catalyst.
• For a 1-3 month relative-value expression, consider long CAH / short COR only after confirmation that CAH's Medical-margin recovery is company-specific and recurring. Target a modest 5-8% relative move; exit if CAH cannot demonstrate operating-margin expansion or if COR reports superior specialty-distribution growth.
• Avoid using HCSG as a proxy trade. Its economics are driven by outsourced facility-services labor and customer utilization, not pharmaceutical-distribution spreads or CAH's capital structure.
• Set an earnings watch item: if CAH raises EPS while operating profit or operating cash flow fails to track, reduce or avoid exposure; that divergence would indicate below-the-line support or working-capital dependence and raises downside risk at the next guidance cycle.